1. Home
  2. VRDN vs BHE Comparison

VRDN vs BHE Comparison

Compare VRDN & BHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRDN
  • BHE
  • Stock Information
  • Founded
  • VRDN 2006
  • BHE 1979
  • Country
  • VRDN United States
  • BHE United States
  • Employees
  • VRDN N/A
  • BHE N/A
  • Industry
  • VRDN Medical Specialities
  • BHE Electrical Products
  • Sector
  • VRDN Health Care
  • BHE Technology
  • Exchange
  • VRDN Nasdaq
  • BHE Nasdaq
  • Market Cap
  • VRDN 1.3B
  • BHE 1.3B
  • IPO Year
  • VRDN N/A
  • BHE 1990
  • Fundamental
  • Price
  • VRDN $15.67
  • BHE $40.32
  • Analyst Decision
  • VRDN Strong Buy
  • BHE Strong Buy
  • Analyst Count
  • VRDN 11
  • BHE 2
  • Target Price
  • VRDN $38.50
  • BHE $47.00
  • AVG Volume (30 Days)
  • VRDN 728.3K
  • BHE 279.8K
  • Earning Date
  • VRDN 08-07-2025
  • BHE 07-29-2025
  • Dividend Yield
  • VRDN N/A
  • BHE 1.69%
  • EPS Growth
  • VRDN N/A
  • BHE N/A
  • EPS
  • VRDN N/A
  • BHE 1.44
  • Revenue
  • VRDN $302,000.00
  • BHE $2,612,294,000.00
  • Revenue This Year
  • VRDN N/A
  • BHE $0.52
  • Revenue Next Year
  • VRDN $17,102.33
  • BHE $8.50
  • P/E Ratio
  • VRDN N/A
  • BHE $27.98
  • Revenue Growth
  • VRDN 4.86
  • BHE N/A
  • 52 Week Low
  • VRDN $9.90
  • BHE $30.73
  • 52 Week High
  • VRDN $27.20
  • BHE $52.57
  • Technical
  • Relative Strength Index (RSI)
  • VRDN 61.91
  • BHE 67.14
  • Support Level
  • VRDN $13.84
  • BHE $38.01
  • Resistance Level
  • VRDN $14.85
  • BHE $39.77
  • Average True Range (ATR)
  • VRDN 0.82
  • BHE 0.92
  • MACD
  • VRDN -0.03
  • BHE 0.17
  • Stochastic Oscillator
  • VRDN 82.81
  • BHE 92.91

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.

Share on Social Networks: